What exactly is a nicotine pouch?

Picture a small white pouch the size of a mint, tucked under the lip. No smoke, no vapor, no spitting. It contains nicotine — extracted from tobacco or synthetic — mixed with flavors, filling agents, and salts. The nicotine passes directly through the oral mucosa into the bloodstream.

The best-known brands are ZYN (Swedish Match), VELO (British American Tobacco), and on! (Altria). They're sold at concentrations ranging from 2 mg to over 8 mg of nicotine, in dozens of flavors — mint, fruit, cinnamon, coffee. It's precisely designed to appeal.

In the US, the FDA regulates them as tobacco products — even without any tobacco leaf — because they contain nicotine. No pouch has yet received authorization as a medical smoking-cessation aid.

Why is it exploding in popularity — especially among young people?

In the US, oral nicotine products have become the second-most used nicotine product among teenagers, just behind e-cigarettes. Between 2019 and 2021, their use among teens rose from 3.5% to 4.1%. And among young adults, up to 29% may be willing to try them.

Why? Complete discretion (no smell, no smoke), convenience (usable anywhere), polished marketing, and above all the perception that they're "tobacco-free so less dangerous." A shortcut that science strongly qualifies.

Less dangerous than a cigarette — really?

That's the central question. Short answer: probably, yes. No combustion, no tar inhalation. Studies show much lower levels of nitrosamines (the main tobacco carcinogens) compared to cigarettes. Inflammation and cardiovascular-exposure biomarkers were reduced by 22 to 97% in pouch users vs. smokers.

The problem with the available studies

Here's where the trouble lies. Nearly all the studies on the pharmacology and health effects of nicotine pouches were funded by the manufacturers themselves — Swedish Match, British American Tobacco, Altria. The authors of this scientific review make this explicit: these results must be verified by independent studies before drawing firm conclusions.

It's not that these studies are wrong — but the potential conflict of interest is real, and science requires independent replication.

Composition and physicochemical characteristics

Nicotine pouches contain either tobacco-derived nicotine (ZYN, VELO, on!) or synthetic nicotine (FRĒ, FR3SH, NIC-S). Most use the nicotine salt form (bitartrate dihydrate), which modulates absorption. Total nicotine content ranges from 1.3 to over 47 mg per pouch depending on brand and strength.

A key parameter is pH: of 44 brands analyzed, 43 have an alkaline pH (median: 8.8). This elevated pH favors the free-base form of nicotine, which is more lipophilic and therefore more easily absorbed by the oral mucosa. Free-nicotine content ranges from 7.7 to 99.2% across products — considerable heterogeneity with real pharmacological implications.

Pharmacokinetics: how much nicotine, and how fast?

Pharmacokinetic studies show that nicotine pouches deliver plasma concentrations similar to those of cigarettes, but with a peak (Cmax) reached much more slowly. Time to nicotine peak (Tmax) is 22 to 65 minutes for pouches, versus 7 to 8 minutes for a cigarette. This slower kinetic profile is associated with probably lower addictive potential — peak speed contributes to the reward effect.

Toxicological profile: substantially better than a cigarette, but not neutral

Industry studies show that levels of tobacco-specific nitrosamines (NNN, NNK), polycyclic aromatic hydrocarbons, and other toxicants are very low in pouches — 22 of 25 tested were non-quantifiable, compared to only 11 for snus. This profile is comparable to FDA-approved NRTs.

However, pouches contain synthetic cooling agents (such as WS-3 in ZYN menthol varieties) and traces of formaldehyde, chromium, and nickel — whose long-term effects during daily oral use are uncharacterized.

Do pouches help people quit smoking?

The data is promising but insufficient. In a 6-week industry-funded trial, 82% of smokers reduced their consumption with VELO pouches — but only 3% quit completely. In another on! trial, 27% of smokers had fully switched to pouches after 6 weeks. These numbers are encouraging, but these studies have significant methodological limitations and weren't compared to FDA-approved cessation methods (varenicline, NRT).

Physicochemistry and nicotine delivery: remarkable heterogeneity

Analysis of 44 brands reveals extreme variance: pH from 6.86 to 10.1, total nicotine content from 1.29 to 6.11 mg/pouch in some analyses, and from 1.8 to 47.5 mg in industry studies. Free nicotine (unprotonated base form) ranges from 0.17 to 6.07 mg/pouch, with a free fraction of 7.7 to 99.2%. This variability has direct clinical implications: transmucosal absorption depends on the free-base fraction (nicotine pKa ≈ 8.02; at alkaline pH, free-base fraction increases per Henderson-Hasselbalch).

Some pouches (2 of 44 tested) reach levels above 40 mg/pouch — a level that raises legitimate questions of acute toxicity, particularly in cases of accidental pediatric ingestion.

Comparative pharmacokinetics: industry study data

The available PK studies (all industry-funded, N = 6 studies) compare NPs to cigarettes, snus, smokeless tobacco, and NRTs. Highlights:

• →Cmax: variable by brand and dose (8.5–18.4 ng/mL for 4–10 mg). Nordic Spirit 9 mg (Cmax 18.4) and Lyft 10 mg (17.1) exceed ZYN 10 mg (11.0), suggesting a major role for formulation beyond nominal dose.
• →Tmax: 22–65 min for NPs vs. 7–8 min for cigarettes. This lag reduces immediate positive reinforcement, a key parameter of abuse potential per pharmacological dependence models.
• →NRT comparison: NP Cmax (8.5 ng/mL for 4 mg) is comparable to the NRT lozenge (8.3 ng/mL) but higher than NRT gum (4.4 ng/mL). An ad libitum study (4h) on NPs at varying concentrations documents inverse dose-consumption: 18 pouches/4h for 1.5 mg vs. 6 pouches/4h for 8 mg — consistent with compensatory titration.

Biomarkers of exposure and potential harm

An industry study (VELO vs. smokers) reports reductions of 22.7 to 97.2% in biomarkers including NNAL (NNK metabolite), NNN, sICAM-1 (inflammation), carboxyhemoglobin, and six exposure biomarkers (3-HPMA, 3-OH-B[a]P, HMPMA, MHBMA, S-PMA, NNN). Several biomarkers (including 8-Epi-PGF2α, an oxidative stress marker) remained similar between NPs and smokers — a signal for vigilance.

A randomized controlled trial (on!, 7 days) shows that exposure biomarkers in smokers switching to NPs approach those of subjects who quit completely — an impressive result, but over 7 days only, in an industry context.

On the oral level: reduction of pre-existing mucosal lesions in snus users switching to NPs (6 weeks), and reduced in vitro pro-inflammatory cytokine production by mononuclear cells exposed to NPs vs. snus. Against that: a cross-sectional survey documents oral adverse events in 25% of current users (ulcers, pain, irritation).

Marketing strategies and regulatory issues

Marketing analysis reveals deliberately targeted strategies: ads predominantly feature white men; VELO dominated ad spending through 2022 (representing nearly 90% of oral nicotine spending) before dropping to zero after the FDA's regulatory authority expanded to non-tobacco nicotine products in April 2022. ZYN has since taken over with the slogan "flavor-ban approved" — messaging that explicitly exploits regulatory restrictions as a selling point.

No manufacturer has yet received an FDA marketing order for its pouches, and none has authorization as a cessation aid (CDER). Lucy markets its products as "PMTA accepted" — implying an authorization that doesn't yet exist. This type of misleading communication illustrates the current regulatory vacuum.